Navigation Links
Amgen to Highlight New Data at Upcoming ESC Congress 2013
Date:8/27/2013

th Cytokinetics.

About the Omecamtiv Mecarbil Clinical Trial Program
The Phase 2b clinical trial known as ATOMIC-AHF (Acute Treatment of Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) is an international, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of an intravenous formulation of omecamtiv mecarbil in approximately 600 patients with left ventricular systolic dysfunction who were hospitalized with acute heart failure.4

Oral formulations of omecamtiv mecarbil are currently being evaluated in a Phase 2 trial known as COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure). COSMIC-HF is a multicenter, randomized, double-blind, placebo-controlled, dose escalation study designed to evaluate the safety and efficacy of oral omecamtiv mecarbil in approximately 420 patients with chronic heart failure and left ventricular systolic dysfunction.5

Additional information about clinical trials of omecamtiv mecarbil can be found at www.clinicaltrials.gov.

About AMG 145
AMG 145 is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood. AMG 145, being developed by Amgen scientists, is designed to bind to PCSK9 and inhibit PCSK9 binding to LDL receptors on the liver's surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood.6

About the AMG 145 Clinical Trial Program
PROFICIO, which stands for the Program to Reduce LDL-C and Cardiovascu
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
2. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
3. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
4. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
5. Amgen Announces Webcast of 2013 Second Quarter Financial Results
6. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
7. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
8. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
9. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
10. Amgen And Astellas Announce Japan Alliance
11. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... 18 Epiphany Biosciences announced results from its Phase ... shingles (herpes zoster) infection. The study,s primary endpoint ... in terms of time to complete crusting of the ... randomized into 3 arms: 1 gram of once-daily ...
... Nov. 18 Covance Inc. (NYSE: CVD ), ... it entered into a biomarker alliance and services agreement with ... biomarker testing to the pharmaceutical industry. , Subject to the ... exclusive third-party provider of multiplexed protein biomarker testing services, and ...
Cached Medicine Technology:Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 2Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 3Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc. 4
(Date:12/17/2014)... Nwe is the co-author of a new weight loss book ... the Ace Medical Weight Loss Center in Rock Hill, SC. ... the industry of weight loss, and how several fad diets ... television shows, however, she says the topic of obesity is ... basic laughs, which she believes impacts whether Americans view it ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... 2014 Project Veritas is releasing a ... of MIT economist and Obamacare architect Jonathan Gruber to ... conducted the interview, which is being distributed on YouTube. ... intentional mislabeling in the Affordable Care Act in order ... two-hundred-and-fifty billion dollar per year tax grab. , “President ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... Attacks New York Department of ,Hype, with New York Times Ad ... (CCF) is running a full-page ad in the New York Times ... Department of Health,s hyperbolic "Don,t drink yourself fat" PSA campaign. The Center ... News and New York Post that ask New Yorkers, ...
... economic times, many business owners cut back and take a ... area cosmetic surgeon, has watched other cosmetic practices lock their ... conclusion that his medical spa and surgery center simply will ... to open another location in the ,Uptown, Dallas area. "I ...
... Oct. 1 Today, MSN released ... that helps people manage their health information on the Web. ... a variety of tools and widgets to upload, organize and ... The new service allows people to research medical concerns, read ...
... ... in stock, but supplies are expected to sell out quickly. Businesses and schools ... Purell on hand before the demand peaks as a result of the H1N1 ... company has 4.25 oz bottles, 12 oz pump bottles, 8 oz pump bottles ...
... ... the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , ... Englewood, CO (Vocus) October 1, ... unveiled the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , , ...
... ... TCSterps On-Demand, a comprehensive Video Relay Interpreting (VRI) service providing Sign Language Interpreting ... ... -- TCS Associates , ( http://www.TCSassociates.com ) a total solutions provider for ...
Cached Medicine News:Health News:Consumer Group Continues Million Dollar Campaign Responding to NYC Health Officials' Hyperbolic PSA Campaign 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 3Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 2Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 3Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 2Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 3Health News:BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 3
... fiscal year 2004, Biomet plans to ... to the global market, enhancing visualization ... Acumen technology was developed in conjunction ... based in Hollywood, Florida. Procedure-specific software ...
... utomated R etinal I maging ... rapid and automated stereo examinations of the retina. ... to screen and diagnose sight-threatening retinal diseases in ... and at lower cost ., ,As ...
The new Riata® i lead family allows physicians even more versatility when managing patients with high defibrillation thresholds (DFTs)....
... Millennium™ microsurgical system delivers on the ... technology. For the latest advancement in ... Bausch & Lomb Surgical offers CONCENTRIX™ ... pump to provide both flow and ...
Medicine Products: